Login to Your Account

Bial clinical trial fiasco clouds rollout of EMA's new operational strategy

By Cormac Sheridan
Staff Writer

Wednesday, April 6, 2016

HAMBURG – The EMA is still waiting on a report from the French regulator Agence Nationale de Sécurité du Médicament et des Produits de Santé (ANSM), in the wake of the clinical trial disaster involving painkiller BIA10-2474, which Porto, Portugal-based Bial Portela & CA was developing.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription